Galectin Therapeutics Inc.
GALT
$1.38
$0.010.73%
NASDAQ
12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
---|---|---|---|---|---|
Net Income | -47.05M | -45.08M | -44.29M | -41.03M | -41.07M |
Total Depreciation and Amortization | 37.00K | 36.00K | 35.00K | 10.00K | 33.00K |
Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
Total Other Non-Cash Items | 2.96M | 4.47M | 4.18M | 3.50M | 3.39M |
Change in Net Operating Assets | 2.28M | 6.89M | 7.29M | 3.25M | 4.68M |
Cash from Operations | -41.77M | -33.68M | -32.78M | -34.28M | -32.97M |
Capital Expenditure | -- | -- | -- | -- | -- |
Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
Cash Acquisitions | -- | -- | -- | -- | -- |
Divestitures | -- | -- | -- | -- | -- |
Other Investing Activities | -- | -- | -- | -- | -- |
Cash from Investing | -- | -- | -- | -- | -- |
Total Debt Issued | 30.00M | 40.00M | 30.00M | 30.00M | 30.00M |
Total Debt Repaid | -- | -- | -- | -- | -- |
Issuance of Common Stock | 1.23M | 376.00K | 10.41M | 10.03M | 10.03M |
Repurchase of Common Stock | -- | -- | -- | -- | -- |
Issuance of Preferred Stock | -- | -- | -- | -- | -- |
Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
Total Dividends Paid | -- | -- | -- | -- | -- |
Other Financing Activities | -- | -- | -- | -- | -- |
Cash from Financing | 31.23M | 40.38M | 40.41M | 40.03M | 40.03M |
Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
Net Change in Cash | -10.54M | 6.70M | 7.63M | 5.76M | 7.07M |